Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Johnson & Johnson

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 2 March 1990:
Vol. 247. no. 4946, pp. 1079 - 1082
DOI: 10.1126/science.2408149

Articles

Science, Vol 247, Issue 4946, 1079-1082
Copyright © 1990 by American Association for the Advancement of Science


articles

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products

TG Lugo, AM Pendergast, AJ Muller, and ON Witte

Department of Microbiology, University of California, Los Angeles 90024.

Oncogenic activation of the proto-oncogene c-abl in human leukemias occurs as a result of the addition of exons from the gene bcr and truncation of the first abl exon. Analysis of tyrosine kinase activity and quantitative measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210bcr-abl and p185bcr-abl proteins. Thus, foreign upstream sequences are important in the deregulation of the kinase activity of the abl product, and the extent of deregulation correlates with the pathological effects of the bcr-abl proteins.





ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products


Science. ISSN 0036-8075 (print), 1095-9203 (online)